ClinicalTrials.gg
CompletedNCT01458574OCTAVEUpdated May 18, 2017Results posted

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

A Phase 3 interventional study of Placebo and CP690,550 in Ulcerative Colitis, sponsored by Pfizer. Completed at 275 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-18.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
593
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.

Enrollment
3rd of 14
593 · median 107
Started
2012
with 3 others
Phase 3
5 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
7 of 14
Pfizer

Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tofacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Janus kinase inhibitor
  • JAK 3 inhibitor
  • inflammatory bowel disease
  • ulcerative colitis
  • OCTAVE
  • CP-690
  • 550
  • tofacitinib
  • Xeljanz
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who met study entry criteria and completed 8-week induction treatment from Study A3921094 or A3921095
  • Subjects who achieved clinical response in Study A3921094 or A3921095
  • Women of must test negative for pregnancy prior to study enrollment
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
  • Evidence of a personally signed and dated document(s) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects who had major protocol violation (as determined by the Sponsor) in Study A3921094 or A3921095
  • Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease
  • Subjects who have had surgery for UC or in the opinion of the investigator, are likely to require surgery for UC during the study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
593 participants (actual)

Study arms

  • Placebo comparator
    Placebo Comparator

    Drug: Placebo

  • Experimental
    CP-690,550 5 mg Arm

    Drug: CP690,550

  • Experimental
    CP-690,550 10 mg Arm

    Drug: CP-690,550

Interventions

  • DrugPlacebo

    Placebo 10 mg orally (PO) twice a day (BID)

  • CP-690,550 5 mg orally (PO) twice a day (BID)

  • CP-690,550 10 mg orally (PO) twice a day (BID)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants In Remission at Week 52

    Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and physician global assessment (PGA), each subscore graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12 where higher score indicating higher disease severity.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants With Mucosal Healing at Week 52

    Mucosal healing in participants was defined by mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.

    Time frame: Week 52

  2. Percentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline

    Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission (among participants with remission at baseline) were reported in this outcome measure.

    Time frame: Week 24, 52

  3. Percentage of Participants in Remission at Week 24

    Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Week 24

  4. Percentage of Participants in Sustained Remission

    Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.

    Time frame: Week 24, 52

  5. Percentage of Participants With Mucosal Healing at Week 24

    Mucosal healing in participants was defined by a mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

    Time frame: Week 24

  6. Percentage of Participants With Sustained Mucosal Healing

    Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  7. Percentage of Participants With Mucosal Healing at Week 24 and 52, Among Participants With Mucosal Healing at Baseline

    Mucosal healing in participants was defined as achieving mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  8. Percentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline

    Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  9. Percentage of Participants With Clinical Response at Week 24 and 52

    Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with clinical response at Week 24 and 52 have been reported in this outcome measure.

    Time frame: Week 24, 52

  10. Percentage of Participants With Sustained Clinical Response

    Sustained clinical response in participants was defined as showing clinical response at both Week 24 and Week 52. Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained clinical response are reported in this outcome measure.

    Time frame: Week 24, 52

  11. Percentage of Participants in Clinical Remission at Week 24 and 52

    Clinical remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  12. Percentage of Participants in Sustained Clinical Remission

    Sustained clinical remission in participants was defined as being in clinical remission at both Week 24 and Week 52. Clinical remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  13. Percentage of Participants in Deep Remission at Week 24 and 52

    Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  14. Percentage of Participants in Sustained Deep Remission

    Sustained deep remission was defined by being in deep remission at both Week 24 and Week 52. Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  15. Percentage of Participants in Symptomatic Remission at Week 24 and 52

    Symptomatic remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub-scores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  16. Percentage of Participants in Sustained Symptomatic Remission

    Sustained symptomatic remission in participants was defined as being in symptomatic remission at both Week 24 and Week 52. Symptomatic remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Week 24, 52

  17. Percentage of Participants in Endoscopic Remission at Week 24 and 52

    Endoscopic remission in participants was defined as a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.

    Time frame: Week 24, 52

  18. Percentage of Participants in Sustained Endoscopic Remission

    Sustained endoscopic remission in participants was defined as being in endoscopic remission at both Week 24 and Week 52. Endoscopic remission was defined by a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.

    Time frame: Week 24, 52

  19. Total Mayo Score at Baseline, Week 24 and 52

    Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

    Time frame: Baseline, Week 24, 52

  20. Change From Baseline in Total Mayo Score at Week 24 and 52

    Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Change from baseline in total mayo score at Week 24 and 52 was reported.

    Time frame: Baseline, Week 24, 52

  21. Percentage of Participants in Remission, Among Participants With Remission at Baseline

    Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.

    Time frame: Week 24, 52

  22. Percentage of Participants in Sustained Remission, Among Participants With Remission at Baseline

    Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.

    Time frame: Week 24, 52

  23. Percentage of Participants in Steroid-free Remission, Among Participants in Remission at Baseline

    Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants in steroid-free remission were reported in this outcome measure.

    Time frame: Week 24, 52

  24. Percentage of Participants in Steroid-Free Remission, Among Participants Receiving Steroids at Baseline

    Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with steroid-free remission were reported in this outcome measure.

    Time frame: Week 24, 52

  25. Percentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline

    Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission were reported in this outcome measure.

    Time frame: Week 24, 52

07

Results

Posted May 18, 2017

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Started198197198
Treated198196198
Completed11112653
Not completed8771145
Withdrew: Adverse event597
Withdrew: Lack of efficacy7053132
Withdrew: Lost to follow-up321
Withdrew: Pregnancy110
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject635
Withdrew: Other210
Withdrew: Randomized but not treated010

Outcome measures

PrimaryPercentage of Participants In Remission at Week 52

Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and physician global assessment (PGA), each subscore graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12 where higher score indicating higher disease severity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants In Remission at Week 52
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants In Remission at Week 5234.340.611.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 23.2 · 95% CI 15.3 to 31.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 29.5 · 95% CI 21.4 to 37.6
SecondaryPercentage of Participants With Mucosal Healing at Week 52

Mucosal healing in participants was defined by mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing at Week 52
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants With Mucosal Healing at Week 5237.445.713.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 24.2 · 95% CI 16.0 to 32.5
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 32.6 · 95% CI 24.2 to 41.0
SecondaryPercentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline

Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission (among participants with remission at baseline) were reported in this outcome measure.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline35.447.35.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 30.3 · 95% CI 17.4 to 43.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 42.2 · 95% CI 27.9 to 56.5
SecondaryPercentage of Participants in Remission at Week 24

Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Remission at Week 24
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Remission at Week 2433.835.511.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 22.7 · 95% CI 14.8 to 30.6
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 24.4 · 95% CI 16.4 to 32.4
SecondaryPercentage of Participants in Sustained Remission

Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Remission
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Sustained Remission22.225.45.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 17.2 · 95% CI 10.6 to 23.7
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 20.3 · 95% CI 13.5 to 27.1
SecondaryPercentage of Participants With Mucosal Healing at Week 24

Mucosal healing in participants was defined by a mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing at Week 24
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants With Mucosal Healing at Week 2443.946.217.2
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 26.8 · 95% CI 18.1 to 35.5
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 29.0 · 95% CI 20.3 to 37.7
SecondaryPercentage of Participants With Sustained Mucosal Healing

Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Mucosal Healing
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants With Sustained Mucosal Healing27.833.06.6
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 21.2 · 95% CI 14.1 to 28.3
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 26.4 · 95% CI 19.0 to 33.8
SecondaryPercentage of Participants With Mucosal Healing at Week 24 and 52, Among Participants With Mucosal Healing at Baseline

Mucosal healing in participants was defined as achieving mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing at Week 24 and 52, Among Participants With Mucosal Healing at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2452.466.321.8
Week 5241.955.111.9
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 30.6 · 95% CI 18.1 to 43.1
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 44.5 · 95% CI 31.8 to 57.2
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 30.0 · 95% CI 18.7 to 41.4
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 43.2 · 95% CI 31.1 to 55.3
SecondaryPercentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline

Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline33.349.48.9
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 24.4 · 95% CI 13.8 to 35.0
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 40.5 · 95% CI 28.7 to 52.3
SecondaryPercentage of Participants With Clinical Response at Week 24 and 52

Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with clinical response at Week 24 and 52 have been reported in this outcome measure.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Week 24 and 52
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2463.670.633.3
Week 5251.561.920.2
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 30.3 · 95% CI 20.9 to 39.7
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 37.2 · 95% CI 28.1 to 46.4
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 31.3 · 95% CI 22.4 to 40.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 41.7 · 95% CI 32.9 to 50.5
SecondaryPercentage of Participants With Sustained Clinical Response

Sustained clinical response in participants was defined as showing clinical response at both Week 24 and Week 52. Clinical response was defined by a decrease from induction study (A3921094 \[NCT01465763\] or A3921095 \[NCT01458951\]) baseline in mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained clinical response are reported in this outcome measure.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Clinical Response
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants With Sustained Clinical Response49.059.419.2
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 29.8 · 95% CI 20.9 to 38.7
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 40.2 · 95% CI 31.4 to 49.0
SecondaryPercentage of Participants in Clinical Remission at Week 24 and 52

Clinical remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission at Week 24 and 52
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2434.335.511.1
Week 5234.341.111.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 23.2 · 95% CI 15.3 to 31.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 24.4 · 95% CI 16.4 to 32.4
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 23.2 · 95% CI 15.3 to 31.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 30.0 · 95% CI 21.9 to 38.2
SecondaryPercentage of Participants in Sustained Clinical Remission

Sustained clinical remission in participants was defined as being in clinical remission at both Week 24 and Week 52. Clinical remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Clinical Remission
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Sustained Clinical Remission22.225.95.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 17.2 · 95% CI 10.6 to 23.7
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 20.8 · 95% CI 14.0 to 27.7
SecondaryPercentage of Participants in Deep Remission at Week 24 and 52

Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Deep Remission at Week 24 and 52
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2414.110.74.0
Week 5214.615.24.0
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0006 · Difference in percentage: 10.1 · 95% CI 4.5 to 15.7
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = 0.0092 · Difference in percentage: 6.6 · 95% CI 1.5 to 11.7
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0004 · Difference in percentage: 10.6 · 95% CI 5.0 to 16.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 11.2 · 95% CI 5.5 to 16.9
SecondaryPercentage of Participants in Sustained Deep Remission

Sustained deep remission was defined by being in deep remission at both Week 24 and Week 52. Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Deep Remission
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Sustained Deep Remission6.13.60.5
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0029 · Difference in percentage: 5.6 · 95% CI 2.1 to 9.0
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = 0.0350 · Difference in percentage: 3.0 · 95% CI 0.3 to 5.8
SecondaryPercentage of Participants in Symptomatic Remission at Week 24 and 52

Symptomatic remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub-scores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Symptomatic Remission at Week 24 and 52
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2423.721.86.6
Week 5222.726.97.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 17.2 · 95% CI 10.3 to 24.0
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 15.3 · 95% CI 8.5 to 22.0
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 15.7 · 95% CI 8.8 to 22.5
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 19.8 · 95% CI 12.7 to 27.0
SecondaryPercentage of Participants in Sustained Symptomatic Remission

Sustained symptomatic remission in participants was defined as being in symptomatic remission at both Week 24 and Week 52. Symptomatic remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Symptomatic Remission
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Sustained Symptomatic Remission13.615.72.5
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 11.1 · 95% CI 5.9 to 16.4
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 13.2 · 95% CI 7.7 to 18.7
SecondaryPercentage of Participants in Endoscopic Remission at Week 24 and 52

Endoscopic remission in participants was defined as a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Endoscopic Remission at Week 24 and 52
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2416.212.24.0
Week 5214.616.84.0
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 12.1 · 95% CI 6.3 to 17.9
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = 0.0021 · Difference in percentage: 8.1 · 95% CI 2.8 to 13.5
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0004 · Difference in percentage: 10.6 · 95% CI 5.0 to 16.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 12.7 · 95% CI 6.8 to 18.6
SecondaryPercentage of Participants in Sustained Endoscopic Remission

Sustained endoscopic remission in participants was defined as being in endoscopic remission at both Week 24 and Week 52. Endoscopic remission was defined by a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Endoscopic Remission
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Sustained Endoscopic Remission6.15.10.5
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0029 · Difference in percentage: 5.6 · 95% CI 2.1 to 9.0
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = 0.0064 · Difference in percentage: 4.6 · 95% CI 1.4 to 7.8
SecondaryTotal Mayo Score at Baseline, Week 24 and 52

Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.

Time frame:
Baseline, Week 24, 52
Reported as:
Mean · units on a scale
Total Mayo Score at Baseline, Week 24 and 52
units on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Baseline (n = 198, 197, 198)3.3 ± 1.83.4 ± 1.83.3 ± 1.8
Week 24 (n = 179, 186, 181)4.1 ± 3.44.0 ± 3.36.7 ± 3.5
Week 52 (n = 129, 137, 68)3.2 ± 3.12.6 ± 2.74.6 ± 3.2
SecondaryChange From Baseline in Total Mayo Score at Week 24 and 52

Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Change from baseline in total mayo score at Week 24 and 52 was reported.

Time frame:
Baseline, Week 24, 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Mayo Score at Week 24 and 52
units on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Change at Week 24 (n = 179, 186, 181)0.3 ± 0.30.0 ± 0.32.9 ± 0.3
Change at Week 52 (n = 129, 137, 68)0.4 ± 0.3-0.4 ± 0.32.9 ± 0.4
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · Linear mixed effect model · p = <0.0001 · Least square mean difference: -2.6 · 95% CI -3.2 to -1.9
  • Tofacitinib 10 mg BID vs Placebo · Linear mixed effect model · p = <0.0001 · Least square mean difference: -2.8 · 95% CI -3.5 to -2.2
  • Tofacitinib 5 mg BID vs Placebo · Linear mixed effect model · p = <0.0001 · Least square mean difference: -2.6 · 95% CI -3.4 to -1.7
  • Tofacitinib 10 mg BID vs Placebo · Linear mixed effect model · p = <0.0001 · Least square mean difference: -3.3 · 95% CI -4.1 to -2.5
SecondaryPercentage of Participants in Remission, Among Participants With Remission at Baseline

Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Remission, Among Participants With Remission at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2455.463.615.3
Week 5246.256.410.2
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 40.1 · 95% CI 25.0 to 55.3
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 48.4 · 95% CI 32.7 to 64.1
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 36.0 · 95% CI 21.6 to 50.3
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 46.2 · 95% CI 31.0 to 61.4
SecondaryPercentage of Participants in Sustained Remission, Among Participants With Remission at Baseline

Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Remission, Among Participants With Remission at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Sustained Remission, Among Participants With Remission at Baseline36.947.35.1
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 31.8 · 95% CI 18.8 to 44.8
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 42.2 · 95% CI 27.9 to 56.5
SecondaryPercentage of Participants in Steroid-free Remission, Among Participants in Remission at Baseline

Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants in steroid-free remission were reported in this outcome measure.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Steroid-free Remission, Among Participants in Remission at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2453.863.615.3
Week 5244.656.410.2
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 38.6 · 95% CI 23.4 to 53.8
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 48.4 · 95% CI 32.7 to 64.1
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 34.4 · 95% CI 20.1 to 48.8
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = <0.0001 · Difference in percentage: 46.2 · 95% CI 31.0 to 61.4
SecondaryPercentage of Participants in Steroid-Free Remission, Among Participants Receiving Steroids at Baseline

Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with steroid-free remission were reported in this outcome measure.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Week 2423.824.110.9
Week 5227.727.610.9
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0074 · Difference in percentage: 12.9 · 95% CI 2.6 to 23.2
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = 0.0103 · Difference in percentage: 13.2 · 95% CI 2.4 to 24.1
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0018 · Difference in percentage: 16.8 · 95% CI 6.2 to 27.5
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = 0.0029 · Difference in percentage: 16.7 · 95% CI 5.5 to 27.9
SecondaryPercentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline

Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission were reported in this outcome measure.

Time frame:
Week 24, 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Percentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline12.916.15.0
Statistical analysis
  • Tofacitinib 5 mg BID vs Placebo · CMH chi-square test · p = 0.0419 · Difference in percentage: 7.9 · 95% CI 0.1 to 15.7
  • Tofacitinib 10 mg BID vs Placebo · CMH chi-square test · p = 0.0121 · Difference in percentage: 11.1 · 95% CI 2.3 to 19.9

Adverse events

Collected over Baseline up to Week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 5 mg BID—10/198 (5.1%)87/198 (43.9%)
Tofacitinib 10 mg BID—11/196 (5.6%)107/196 (54.6%)
Placebo—13/198 (6.6%)108/198 (54.5%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Colitis ulcerativeGastrointestinal disorders2/1981/1968/198
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/950/861/82
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/950/860/82
Abdominal painGastrointestinal disorders0/1981/1960/198
DiarrhoeaGastrointestinal disorders0/1981/1960/198
Cholecystitis acuteHepatobiliary disorders0/1981/1960/198
Bacterial diarrhoeaInfections and infestations0/1981/1960/198
Spinal compression fractureInjury, poisoning and procedural complications0/1981/1960/198
OsteoarthritisMusculoskeletal and connective tissue disorders0/1981/1960/198
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1981/1960/198
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo
Colitis ulcerativeGastrointestinal disorders35/19829/19664/198
NasopharyngitisInfections and infestations19/19827/19611/198
ArthralgiaMusculoskeletal and connective tissue disorders17/19817/19619/198
HeadacheNervous system disorders17/1986/19612/198
Blood creatine phosphokinase increasedInvestigations6/19813/1964/198
Upper respiratory tract infectionInfections and infestations13/19812/1967/198
HypercholesterolaemiaMetabolism and nutrition disorders4/19811/1962/198
RashSkin and subcutaneous tissue disorders6/19811/1968/198
Abdominal painGastrointestinal disorders5/1987/19611/198
FatigueGeneral disorders8/1984/19611/198

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDPlaceboTotal
Mean41.9 ± 13.742.9 ± 14.443.4 ± 1442.7 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDPlaceboTotal
Female958782264
Male103110116329
08

Study locations

275 sites
  • Internal Medicine Center, LLC
    Mobile, Alabama 36608, United States
  • Springhill Memorial Hospital (Endoscopy Only)
    Mobile, Alabama 36608, United States
  • UCSD Health System - Investigational Drug Pharmacy - Moores Cancer Center
    La Jolla, California 92037-0845, United States
  • UCSD Medical Center
    La Jolla, California 92093, United States
  • Alliance Clinical Research
    Oceanside, California 92056, United States
  • Desert Advanced Imaging
    Palm Springs, California 92262, United States
  • Erik Palmer, DO
    Palm Springs, California 92262, United States
  • Homan A Zadeh, MD, MPH
    Palm Springs, California 92262, United States
  • Hope Square Surgical Center
    Rancho Mirage, California 92270, United States
  • Sharp Rees-Stealy Medical Group, Inc.
    San Diego, California 92101, United States
  • Clinical Applications Laboratories, Inc
    San Diego, California 92103, United States
  • San Diego Endoscopy Center
    San Diego, California 92103, United States
  • Sharp Rees-Stealy Medical Group
    San Diego, California 92123, United States
  • UCSF Endoscopy Unit at Mount Zion
    San Francisco, California 94115, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • Bristol Hospital
    Bristol, Connecticut 06010, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Endoscopy Center of Connecticut, LLC
    Guilford, Connecticut 06437, United States
  • Endoscopy Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Gastroenterology Center of Connecticut, PC
    Hamden, Connecticut 06518, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Central Connecticut Endoscopy Center
    Plainville, Connecticut 06062, United States
  • Citrus Surgery & Endoscopy Center (colonoscopy)
    Crystal River, Florida 34429, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Suncoast Endoscopy Center (colonoscopy)
    Inverness, Florida 34453, United States
  • North Florida Gastroenterology Research, LLC
    Orange Park, Florida 32073, United States
  • Citrus Ambulatory Surgery Center
    Orlando, Florida 32806, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Advanced Gastroenterology Center
    Port Orange, Florida 32127, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Endoscopy Center
    Port Orange, Florida 32127, United States
  • Port Orange Urgent Care
    Port Orange, Florida 32127, United States
  • Florida Medical Clinic, P.A.
    Zephyhills, Florida 33542, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Georgia Endoscopy Center
    Alpharetta, Georgia 30005, United States
  • GI Consultants
    Atlanta, Georgia 30342, United States
  • Emory Healthcare Heart Center
    Johns Creek, Georgia 30097, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • Johns Creek Diagnostic Center
    Suwanee, Georgia 30024, United States
  • Cotton-O'Neal Clinical Research Center Digestive Health
    Topeka, Kansas 66606, United States
  • Digestive Disease Associates, PA
    Baltimore, Maryland 21229, United States
  • Gastrointestinal Diagnostic Center
    Baltimore, Maryland 21229, United States
  • Digestive Disease Associates, PA
    Catonsville, Maryland 21228, United States
  • Howard County GIDC
    Columbia, Maryland 21044, United States
  • Saint Joseph Mercy Hospital - Inpatient Pharmacy
    Ann Arbor, Michigan 48106, United States
  • East Ann Arbor Health and Geriatrics Center - UMHS
    Ann Arbor, Michigan 48109-2701, United States
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109-5000, United States
  • Michigan Clinical Research Unit - UMHS
    Ann Arbor, Michigan 48109-5872, United States
  • Medical Science Research Building 1 - UMHS
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Surgical Centers of Michigan
    Troy, Michigan 48098, United States
  • Utica Surgery Center (Endoscopy Only)
    Utica, Michigan 48317, United States
  • Michigan Heart SJMH
    Ypsilanti, Michigan 48106, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • Saint Joseph Mercy Hospital Outpatient Laboratory
    Ypsilanti, Michigan 48197, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbour Township, New Jersey 08234, United States
  • South Jersey Gastroenterology
    Marlton, New Jersey 08053, United States
  • The Endo Center at Voorhees
    Vorhees, New Jersey 08043, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • NYU Langone Nassau Gastroenterology Associates
    Great Neck, New York 11021, United States
  • The Private Practice of Simon Lichtiger, MD
    New York, New York 10028, United States
  • IBD Center - The Mount Sinai Hospital
    New York, New York 10029, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • CUMC Research Pharmacy
    New York, New York 10032, United States
  • Kornbluth, Legnani, George MD, PC
    New York, New York 10128, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Carolina Research, Carolina Digestive Diseases
    Greenville, North Carolina 27834, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195-0001, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • Mentor Medical Campus
    Mentor, Ohio 44060, United States
  • The Endoscopy Center of Lake County
    Mentor, Ohio 44060, United States
  • Regional Gastroenterology Associates of Lancaster, Ltd.
    Lancaster, Pennsylvania 17604, United States
  • Professional Quality Research, Inc.- Austin Gastroenterology PA
    Austin, Texas 78705, United States
  • Austin Endoscopy Center II
    Austin, Texas 78745, United States
  • Austin Gastroenterology PA
    Austin, Texas 78745, United States
  • Houston Hospital for Specialized Surgery (Endoscopy only)
    Houston, Texas 77004, United States
  • Baylor College of Medicine (Baylor Medical Center)
    Houston, Texas 77030, United States
  • Baylor College of Medicine - Baylor Medical Center (Drug Storage)
    Houston, Texas 77030, United States
  • McGovern Medical School -The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Memorial Hermann Hospital
    Houston, Texas 77030, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • Alpine Medical Group
    Salt Lake City, Utah 84102, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
  • Wasatch Endoscopy Center
    Salt Lake City, Utah 84124, United States
  • VCU Health System Digestive Health Center
    Richmond, Virginia 23298, United States
  • VCU Health System Endoscopy Suite
    Richmond, Virginia 23298, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • The Center for Digestive Health
    Milwaukee, Wisconsin 53215, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Eastern Health-Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • AKH Wien, Universitaetsklinik fuer Innere Medizin III
    Wien, Vienna 1090, Austria
  • GZA St. Vincentius
    Antwerpen, 2018, Belgium

Showing the first 100 of 275 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, Sawyerr G, Shi H, Su C, Judd DT, Jones T, Loftus EV. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084. PubMed 36342120 ↗
  • Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2023 Mar;16(2):95-103. doi: 10.1007/s40271-022-00603-w. Epub 2022 Nov 7. PubMed 36336750 ↗
  • Winthrop KL, Vermeire S, Long MD, Panes J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2023 Jan 5;29(1):85-96. doi: 10.1093/ibd/izac063. PubMed 35648151 ↗
  • Vavricka SR, Greuter T, Cohen BL, Reinisch W, Steinwurz F, Fellmann M, Guo X, Lawendy N, Paulissen J, Peyrin-Biroulet L. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. Therap Adv Gastroenterol. 2022 May 10;15:17562848221090834. doi: 10.1177/17562848221090834. eCollection 2022. PubMed 35574426 ↗
  • Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther. 2022 Jul;112(1):90-100. doi: 10.1002/cpt.2601. Epub 2022 Apr 27. PubMed 35380740 ↗
  • Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1442-1453. doi: 10.1111/apt.16626. Epub 2021 Oct 6. PubMed 34614208 ↗
  • Farraye FA, Qazi T, Kotze PG, Moore GT, Mundayat R, Lawendy N, Sharma PP, Judd DT. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Aliment Pharmacol Ther. 2021 Aug;54(4):429-440. doi: 10.1111/apt.16439. Epub 2021 Jun 24. PubMed 34165201 ↗
  • Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, Maller E, Fellmann M, Lawendy N, Modesto I, Vavricka SR, Lichtenstein GR. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol. 2021 May 16;14:17562848211005708. doi: 10.1177/17562848211005708. eCollection 2021. PubMed 34035832 ↗
  • Panes J, Vermeire S, Dubinsky MC, Loftus EV, Lawendy N, Wang W, Salese L, Su C, Modesto I, Guo X, Colombel JF. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. J Crohns Colitis. 2021 Nov 8;15(11):1852-1863. doi: 10.1093/ecco-jcc/jjab065. PubMed 33884415 ↗
  • Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 Mar;20(3):591-601.e8. doi: 10.1016/j.cgh.2021.02.043. Epub 2021 Mar 6. PubMed 33684552 ↗
  • Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021 Mar;10(3):229-240. doi: 10.1002/cpdd.899. Epub 2021 Jan 29. PubMed 33513294 ↗
  • Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan(R) Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis. 2021 Aug 19;27(9):1394-1408. doi: 10.1093/ibd/izaa289. PubMed 33324993 ↗
  • Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):116-125.e5. doi: 10.1016/j.cgh.2020.10.004. Epub 2020 Oct 9. PubMed 33039585 ↗
  • Sands BE, Colombel JF, Ha C, Farnier M, Armuzzi A, Quirk D, Friedman GS, Kwok K, Salese L, Su C, Taub PR. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflamm Bowel Dis. 2021 May 17;27(6):797-808. doi: 10.1093/ibd/izaa227. PubMed 32870265 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panes J. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2021 May 17;27(6):816-825. doi: 10.1093/ibd/izaa199. PubMed 32766762 ↗
  • Sandborn WJ, Panes J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9. PubMed 31599001 ↗
  • Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3. doi: 10.1016/j.cgh.2019.04.059. Epub 2019 May 8. PubMed 31077827 ↗
  • Sandborn WJ, Panes J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23. PubMed 30476584 ↗
  • Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131. PubMed 29850873 ↗
  • Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018 Apr;16(2):233-245. doi: 10.5217/ir.2018.16.2.233. Epub 2018 Apr 30. Erratum In: Intest Res. 2018 Jul;16(3):499-501. doi: 10.5217/ir.2018.16.3.499. PubMed 29743836 ↗
  • Panes J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133. Erratum In: J Crohns Colitis. 2019 Jan 1;13(1):139-140. doi: 10.1093/ecco-jcc/jjy135. PubMed 29028981 ↗
  • Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910. PubMed 28467869 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in May 2016, 46 months.

Results were first posted in May 2017, 11 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 46 months is close to that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2011
First posted
Oct 25, 2011
StartActual
Jul 20, 2012
Primary completionActual
May 27, 2016
CompletionActual
May 27, 2016
Results first posted
May 18, 2017
Last update
May 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01458574
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 25, 2011
Start date
Jul 20, 2012
Primary completion
May 27, 2016
Completion
May 27, 2016
Results posted
May 18, 2017
Last update
May 18, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion